Skip to main content

Table 1 Baseline characteristics of the study patients

From: Strain ultrasonic elastography imaging features of locally advanced breast cancer: association with response to neoadjuvant chemotherapy and recurrence-free survival

Characteristic

pCR

Non-pCR

P value

Recurrence Group

Nonrecurrence Group

Total number

P Value

Number of lesionsb

49 (40.16)

73 (59.83)

 

18 (14.75)

104 (85.24)

122

 

Age (y) a

51 (26–70)

51 (25–70)

0.135

50 (25–67)

52 (26–70)

ZZ

0.61

Tumor diameter (cm) a

4.0 (1.4–8.4)

4.4 (2.2–10.0)

0.14

4.8 (2.1–10.0)

4.1 (1.4–8.7)

 

0.097

Menopausal statusb

  

0.395

   

0.508

 Premenopausal

23 (46.94)

40 (54.79)

 

8 (44.44)

55 (52.88)

63 (51.22)

 

 Postmenmopausal

26 (53.06)

33 (45.21)

 

10 (55.56)

49 (47.12)

59 (48.36)

 

Clinical T stageb

  

0.039

   

<  0.001

 T1 ~ 3

40 (81.63)

47 (64.38)

 

6 (33.33)

81 (77.88)

87 (71.31)

 

 T4

9 (18.37)

26 (35.62)

 

12 (66.67)

23 (22.12)

35 (28.69)

 

Clinical N stageb

  

0.33

   

0.01

 N0 ~ 2

44 (89.79)

61 (83.56)

 

12 (66.67)

93 (89.42)

105(86.07)

 

 N3

5 (10.21)

12 (16.44)

 

6 (33.33)

11 (10.48)

17 (13.93)

 

ER statusb

  

0.005

   

0.803

 ER negative

19 (38.78)

12 (16.44)

 

5 (27.78)

26 (25)

31 (25.41)

 

 ER positive

30 (61.22)

61 (83.56)

 

13 (72.22)

78 (75)

91 (74.59)

 

PR statusb

  

0.02

   

0.641

 PR negative

17 (34.69)

12 (16.44)

 

3 (16.67)

26 (25)

29 (23.77)

 

 PR positive

32 (65.31)

61 (83.56)

 

15 (83.33)

78 (75)

93 (76.23)

 

HER2 statusb

  

0.001

   

0.312

 HER2 negative

18 (36.73)

50 (68.49)

 

12 (66.67)

56 (53.85)

68 (55.74)

 

 HER2 positive

31 (63.27)

23 (31.51)

 

6 (33.33)

48 (46.15)

54 (44.26)

 

Ki-67 indexb

  

0.064

   

0.905

 ≥30

43 (87.76)

54 (73.97)

 

15 (83.33)

82 (78.85)

97 (79.51)

 

 <30

6 (12.24)

19 (26.03)

 

3 (16.67)

22 (21.15)

25 (20.49)

 

Molecular subtypeb

  

0.001

   

0.358

 Luminal A-like

0 (0)

10 (13.70)

 

3 (16.67)

7 (6.73)

10 (8.20)

 

 Luminal B-like (HER2 positive)

22 (44.90)

19 (26.03)

 

4 (22.22)

37 (35.58)

41 (33.33)

 

 Luminal B-like (HER2 negative)

14 (28.57)

36 (49.31)

 

9 (50)

41 (39.42)

50 (40.98)

 

 Triple-negative

4 (8.16)

4 (5.48)

 

0 (0)

8 (7.70)

8 (6.56)

 

 HER2-enriched

9 (18.37)

4 (5.48)

 

2 (11.11)

11 (10.58)

13 (10.67)

 

BMIb

  

0.675

   

0.55

 <25

34 (69.39)

48 (65.75)

 

11 (61.11)

71 (68.27)

82 (67.21)

 

 ≥25

15 (30.61)

25 (34.24)

 

7 (38.89)

33 (31.73)

40 (32.79)

 

SE parameters before NAC

       

 ES

4.43 ± 0.74

4.41 ± 0.57

0.54

4.44 ± 0.62

4.41 ± 0.65

 

0.907

 SR

11.86 ± 4.57

13.10 ± 5.66

0.4

18.44 ± 7.32

11.60 ± 4.09

 

<  0.001

 HP

98.86 ± 2.87

99.43 ± 0.90

0.97

99.91 ± 0.19

99.01 ± 2.10

 

0.004

 AR

112.73 ± 14.17

112.78 ± 12.04

0.985

126.78 ± 16.13

110.34 ± 10.57

 

<  0.001

  1. Data are number of patients and data in parentheses are percentages. pCR Pathologic complete response, ER Estrogen receptor, PR Progesterone receptor, HER2 Human epidermal growth factor receptor 2, Luminal A-like (ER-positive and/or PR-positive, HER2-negative, and Ki-67 expression < 14%), Luminal B-like/HER2-positive (ER-positive and/or PR-positive; HER2-positive and Ki-67 expression ⩾ 14%), Luminal B-like/HER2-negative (ER-positive and/or PR-positive; HER2-negative and Ki-67 expression ⩾ 14%), HER2-enriched (ER and PR-negative, and HER2-positive), and Triple-negative (ER-negative, PR-negative, and HER2-negative). BMI Body mass index, SE Strain elastography, NAC Neoadjuvant chemotherapy, ES Elasticity score, SR Strain ratio, HP Hardness percentage, AR Area ratio
  2. aData are medians, with ranges in parentheses
  3. bData in the parentheses are percentage
Back to article page

BMC Medical Imaging

ISSN: 1471-2342

Contact us